Posted by Michael Wonder on 18 Sep 2017
Seqirus receives FDA approval of Afluria Quadrivalent (influenza vaccine) for people five years of age and older in the U.S.
14 September 2017 - Expanded Afluria Quadrivalent age indication offers protection against four influenza virus strains for people five years of age and older, and increases vaccine options for health care providers and their patients.
Seqirus announced today that the U.S. FDA has approved Afluria Quadrivalent (influenza vaccine) for use in people five years of age and older, extending the company's broad portfolio of influenza vaccine offerings.
Afluria Quadrivalent, which was first approved in the U.S. in August 2016 for people aged 18 and older, helps protect against two influenza A strain viruses and two B strain viruses.
